News
EPIX
1.860
+1.64%
0.030
Weekly Report: what happened at EPIX last week (1223-1227)?
Weekly Report · 12/30/2024 10:57
Weekly Report: what happened at EPIX last week (1216-1220)?
Weekly Report · 12/23/2024 11:03
ESSA Pharma’s Cash Management: A Potential Risk to Shareholder Value and Market Stability
TipRanks · 12/18/2024 06:00
ESSA Pharma Inc. Reports Strategic Shift Amid Losses
TipRanks · 12/18/2024 03:51
ESSA Pharma Inc. (EPIX) Announces Annual Report for Fiscal Year Ended September 30, 2024
Press release · 12/17/2024 20:50
ESSA Pharma Inc reports results for the quarter ended September 30 - Earnings Summary
Reuters · 12/17/2024 13:13
Essa Pharma reports Q4 EPS (14c), consensus (27c)
TipRanks · 12/17/2024 12:05
ESSA Pharma GAAP EPS of -$0.14 beats by $0.05
Seeking Alpha · 12/17/2024 12:03
ESSA PHARMA INC: QTRLY LOSS PER SHARE $0.14
Reuters · 12/17/2024 12:00
ESSA PHARMA INC <EPIX.O> Q4 SHR VIEW $-0.20 -- LSEG IBES DATA
Reuters · 12/17/2024 12:00
ESSA PHARMA INC: STRATEGIC REVIEW EXPECTED TO INVOLVE HEADCOUNT AND OTHER COST REDUCTIONS
Reuters · 12/17/2024 12:00
ESSA PHARMA INC: INITIATED COMPREHENSIVE PROCESS TO EXPLORE AND REVIEW A RANGE OF STRATEGIC OPTIONS
Reuters · 12/17/2024 12:00
Press Release: ESSA Pharma Provides Corporate -2-
Dow Jones · 12/17/2024 12:00
*Essa Pharma 4Q Loss/Shr 14c >EPIX
Dow Jones · 12/17/2024 12:00
ESSA Pharma: Fiscal Q4 Earnings Snapshot
Barchart · 12/17/2024 06:15
ESSA PHARMA INC - TERMINATES LICENSE AGREEMENT WITH BRITISH COLUMBIA CANCER AGENCY AND UBC
Reuters · 12/16/2024 11:13
Weekly Report: what happened at EPIX last week (1209-1213)?
Weekly Report · 12/16/2024 11:04
Weekly Report: what happened at EPIX last week (1202-1206)?
Weekly Report · 12/09/2024 11:03
ESSA Pharma Inc <EPIX.OQ> expected to post a loss of 19 cents a share - Earnings Preview
Reuters · 12/06/2024 13:35
ESSA Pharma Introduces New Executive Severance Plan
TipRanks · 12/06/2024 12:30
More
Webull provides a variety of real-time EPIX stock news. You can receive the latest news about Essa Pharma through multiple platforms. This information may help you make smarter investment decisions.
About EPIX
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).